期刊
HUMAN GENE THERAPY
卷 34, 期 9-10, 页码 345-349出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2023.29242.ddu
关键词
Duchenne muscular dystrophy (DMD); adeno-associated virus (AAV); exon skipping; microdystrophin; CRISPR editing; gene therapy
Duchenne muscular dystrophy (DMD) gene therapy has made significant progress, but faces various challenges in clinical translation. The latest developments and future directions of DMD gene therapy are discussed in this issue of Human Gene Therapy, providing valuable insights for the treatment of other neuromuscular diseases.
Duchenne muscular dystrophy (DMD) was named more than 150 years ago. About four decades ago, the DMD gene was discovered, and the reading frame shift was determined as the genetic underpinning. These pivotal findings significantly changed the landscape of DMD therapy development. Restoration of dystrophin expression with gene therapy became a primary focus. Investment in gene therapy has led to the approval of exon skipping by regulatory agencies, multiple clinical trials of systemic microdystrophin therapy using adeno-associated virus vectors, and revolutionary genome editing therapy using the CRISPR technology. However, many important issues surfaced during the clinical translation of DMD gene therapy (such as low efficiency of exon skipping, immune toxicity-induced serious adverse events, and patient death). In this issue of Human Gene Therapy, several research articles highlighted some of the latest developments in DMD gene therapy. Importantly, a collection of articles from experts in the field reviewed the progress, major challenges, and future directions of DMD gene therapy. These insightful discussions have significant implications for gene therapy of other neuromuscular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据